Xi'an International Medical Investment

Xi'an International Medical Investment

Xi'an International Medical Investment traces its lineage to 1956, though its current identity took shape through a dramatic corporate restructuring led by controlling shareholder Shaanxi Century Xinhai Investment Group and its chairman, Liu Jianxin. The firm was originally known as a commercial retail enterprise, operating the Kaiyuan Commercial chain, but fully exited that business in 2018 when Yintai Group acquired the retail assets for approximately 3.36 billion CNY. That transaction marked the firm's full transformation into a healthcare services operator. Today the firm's strategy concentrates on owning and operating large-scale hospital assets in China's Shaanxi province. Its flagship is the Xi'an International Medical Center Hospital, located in the city's High-tech Zone, which serves as the clinical hub for advanced care. The network also includes Xi'an Gaoxin Hospital and the Xi'an International Medical Center North Campus. The institution has structured its clinical capabilities through international partnerships rather than organic development alone — signing a long-term strategic partnership with Philips for advanced medical imaging and a collaboration with the Mayo Clinic to develop the Mayo (Xi'an) Cancer Hospital. The firm operates through at least four hospital campuses and a mixed-use commercial business center in Xi'an. It recently extended its footprint to Shangluo with the Shangluo International Medical Center Hospital. The controlling parent, Shaanxi Century Xinhai Investment Group, provides strategic direction under Liu Jianxin. The firm also maintains a philanthropic arm, the Sanqin Good Star Charitable Initiative, though the operational relationship between the charitable entity and the commercial hospitals is not publicly detailed. The Philips and Mayo Clinic partnerships were publicly announced, positioning the firm's facilities as receiving external clinical and technology validation. Xi'an International Medical Investment is structurally unusual as a publicly listed corporate investor that behaves like a pure-play hospital operator, yet is controlled by a private investment group. Its predecessor retail business and subsequent pivot to healthcare mirrors a pattern seen in some regional Chinese conglomerates where a government or private backer redirects a listed entity's capital toward a policy-aligned sector. The strategic choice to build a cancer hospital with Mayo Clinic, rather than a domestic partner, signals an outward-facing procurement model not commonly pursued by provincial Chinese hospital groups of this size.